Mechanisms offsetting the beneficial effects of antihypertensive drugs: A problem increasingly considered but incompletely understood

American Journal of Therapeutics

Volumn 5, Issue 6, 1998, Pages 413-419

  Cleophas, T J M ^a  

^a Merwede Ziekenhuis   (Netherlands)

Author keywords

Angiotensin II receptor antagonists; Angiotensin converting enzyme (ACE) inhibitors; Antihypertensive drugs; Calcium channel blockers; Diuretics; Hypertension; blockers

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADRENERGIC SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; INDIVIDUALITY; PRIORITY JOURNAL; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 0031792077     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199811000-00010     Document Type: Review

References (60)

1. Wieling W: Reflex control heart rate in normal subjects in relation to age: a data base for cardiac vagal neuropathy. Diabetologia 1982;22:163-166.
2. Hollenberg NK: Serotonin and vascular responses. Annu Rev Pharmacol Toxicol 1988;28:41-59.
3. Nishimura J, van Breemen C: Direct regulation of smooth muscle contractile elements by second messengers. Biochem Biophys Res Commun 1989;163:929-939.
4. Houben H, Thien T, van't Laar A: Effects of low-dose epinephrine infusion on hemodynamics after selective and non-selective beta-blockade in hypertension. Clin Pharmacol Ther 1982;31:685-690.
5. Goldberg LI, Rajfer EI: Dopamine receptors, applications in clinical cardiology. Circulation 1985;72:245-248.
6. Fitzgerald GA, Murray R, Moran N: Mechanisms of eicosanoid action. Adv Prostaglandin Thromboxane Leukot Res 1991;21B:577-580.
7. Cleophas TJM, Kalmansohn RB: To beta-block or better block. Br Med J 1996;11:167-168.
8. Garcia SR, Bund SJ, Izzard AS, et al: Myogenic tone in resistance arteries from spontaneously hypertensive rats. J Vasc Res 1996;33(Suppl 2):42.
9. Koller A, Huang A, Sun D: Endothelium independent factors augment myogenic tone in hypertension. J Vasc Res 1996;33(Suppl 2):7.
10. Saruta T, Kumagai H: The sympathetic nervous system in hypertension and renal disease. Curr Opin Nephrol Hypertens 1996;5:72-80.
11. Braam B, Koomans HA: Renal responses to antagonism of the renin-angiotensin system. Curr Opin Nephrol Hypertens 1996;5:89-97.
12. Cleophas TJM: A pressor effect of non-selective beta-blockers in diabetics with postural hypotension. In: Beta-Blockers in Hypertension and Angina Pectoris (Ed Cleophas TJM), Kluwer Academic Publishers, Dordrecht, Netherlands, 1995, pp 34-44.
13. Baylis C, Vallance P: Nitric oxide and blood pressure: Effects of nitric oxide deficiency. Curr Opin Nephrol Hypertens 1996;5:80-89.
14. Hiruda Y: Endothelin peptides. Curr Opin Nephrol Hypertens 1996;5:12-16.
15. Taddei S, Virdis A, Mattei P, et al: Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993;21:929-933.
16. Hayashi K, Loutzenhiser R, Epstein M, et al: Multiple factos contribute to acetylcholine-induced renal afferent arteriolar vasodilation during myogenic and norepinephrine- and KCL-induced vasoconstriction. Cire Res 1994;75:821-828.
17. Kanai AJ, Strauss HC, Truskey GA, et al: Shear stress induces ATP-independent nitric oxide release from the vascular endothelial cells. Circ Res 1995;77:284-293.
18. Bauersachs J, Popp R, Hecker M, et al: Attenuated nitric oxide release triggers the release of endothelium derived hyperpolarizing factor. Circulation 1996;94:3341-3347.
19. Lerman A, Burnett JC Jr: Intact and altered endothelium in regulation of vasomotion. Circulation 1992;86(Suppl 3):12-19.
20. Intersalt Cooperative Research Group: Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24-hour urinary sodium and potassium excretion. Br Med J 1988;247:319-328.
21. Cook NB, Cutter JA, Hennekens CH: An unexpected result for sodium causal or casual? Hypertension 1995; 25:1154-1155.
22. Alderman MH, Madhaven S, Cohen H, et al: Low urinary sodium is associated with greater risk of myocardial infarction among treated hypertensive men. Hypertension 1995;25:1144-1152.
23. Mitchell KD, Braun B, Navar LG: Hypertensinogenic mechanisms mediated by the intrarenal actions of reninangiotensin system. Hypertension 1992;19(Suppl 1):18-27.
24. Taddei S, Virdis A, Mattei P, et al. Angiotensin II and sympathetic activity in sodium-restricted essential hypertension. Hypertension 1995;25:595-601.
25. Townend JM, Al-Aui M, West JN, et al: Modulation of cardiac automatic control in humans by angiotensin II. Hypertension 1995;25:1270-1275.
26. Braun B, Koomans HA: Nitric oxide antagonizes the actions of angiotensin II to enhance tubuloglomerular feedback responsiveness. Kidney Int 1995;48:1406-1411.
27. Kumagai H, Suzuki H, Ischikawa M, et al: Different responses of blood flow and sympathetic nerve activity to captopril and nicardipine in conscious renal hypertensive rabbits. J Cardiovasc Pharmacol 1995;25:57-64.
28. Takishita S, Muratani H, Sesoko S, et al: Short-effects of angiotensin II blockade on renal blood flow and sympathetic activity in awake rats. Hypertension 1994;24:445-450.
29. Kamagai K, Reid IA: Angiotensin II exerts differential actions on renal nerve activity and heart rate. Hypertension 1994;24:451-456.
30. 1 receptor antagonist irbesan in hypertension. Hypertension 1995; 25:22-29.
31. Bevan JA, Bevan RD, Huo J, et al: Calcium, intrinsic and extrinsic myogenic tone. In: International Symposium on Calcium Modulators (Eds Godfraind T, Albertini A, Paoletti R), Elsevier Biomedical Press, Amsterdam, 1982, pp 125-132.
32. Lehmann HV, Hochrein H, Witt E, et al: Hemodynamic effects of calcium antagonists. Hypertension 1983;5:66-73.
33. Frishman WH, Stroh JA, Greenberg SM, et al: Calcium channel blockers in systemic hypertension. Curr Probl Cardiol 1987;12:285-346.
34. Weir MR, Dzau VJ, Sasamura H, et al: Efficacy, tolerability, and quality of life of losartan versus nifedipine GITS in patients with essential hypertension. Clin Ther 1996;18:411-428.
35. Ruzicka M, Leenen FHH: Relevance of intermittent increases in sympathetic activity for adverse outcome on short-acting calcium antagonists. In: Hypertension, Pathophysiology, Diagnosis and Management (Eds Laragh JH, Brenner BM), Raven Press, New York, 1995, pp 2815-2825.
36. Francis GS: Calcium channel blockers and congestive heart failure. Circulation 1991;83:336-338.
37. Packer M: Pathophysiological mechanisms underlying the adverse effects of calcium-channel blocking drugs in patients with chronic heart failure. Circulation 1989;80:59-67.
38. Cohen JD: 1995: the year of the calcium antagonist controversy. Curr Opin Nephrol Hypertens 1996;5:214-218.
39. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. NIH Publication no. 93-1088, 1993.
40. Smith WL: The eicosanoids and their biochemical mechanisms of action. Biochem J 1989;259:315-320.
41. Johnson DB, Dell Italia LJ: Cardiac hypertrophy and failure in hypertension. Curr Opin Nephrol Hypertens 1996;5:186-191.
42. Ferrara N, Bunting S: Vascular endothelial growth factor, a specfic regulator of angiogenesis. Curr Opin Nephrol Hypertens 1996;5:35-45.
43. Amann K, Ritz E: Cardiac structure and function in renal disease. Curr Opin Nephrol Hypertens 1996;5:102-106.
44. Wareham NJ, Byrne CD, Hales CN: Role of insulin and proinsulin in diabetic vascular disease. Metabolism 1995;44(Suppl 4):76-82.
45. Atkins FL, Bing OHL, DiMauro PG, et al: Modulation of ventricular beta-adrenergic receptors from spontaneously hypertensive rats with left ventricular hypertrophy and failure. Hypertension 1995;26:78-82.
46. Westphall D, Gerthoffer WT: Vasodilators. In: Human Pharmacology (Eds Brady JM, Larner J, Minnemann KP, et al), 1994, Mosby-Year Book, St. Louis, pp 215-223.
47. Psaty BM, Heckbert SR, Koepsell TD, et al: The risk of myocardial infarction associated with anti-hypertensive drugs therapies. JAMA 1995;274:620-625.
48. Furberg CD, Psaty BM, Meyer JV: Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-1331.
49. Hashimoto J, Imac Y, Minami N, et al: Compliance with long-term dietary salt-restriction in hypertensive outpatients. Clin Exp Hypertens 1994;16:729-739.
50. Wong FS, Miller JA, Blendis LM, et al: Effect of insulin on the vasoconstrictive response to norepinephrine in normal human subjects: the influence of sodium status. Am J Hypertens 1994;7:1097-1104.
51. Opie LH, Messerli FH: Nifedipine and mortality: grave defects in the dossier. Circulation 1995;92:1068-1073.
52. Lindqvist M, Kahan T, Melcher A, et al: Acute and chronic calcium antagonist treatment elevates sympathetic activity in primary hypertension. Hypertension 1994;24:287-296.
53. Frisk-Holmberg M, Paalzow L, Wibell L: Relationship between cardiovascular effects and steady-state kinetics of clonidine in hypertension. Eur J Clin Pharmacol 1984; 26:309-313.
54. van Zwieten TA, Hamilton CA, Prichard BNC: The I-1-Imidazoline Receptor Agonist Monoxidine, Roy Soc Med Services, Alden Press, Oxford, UK, 1994.
55. Vanhoutte P: Serotoninergic mechanisms in hypertension: focus on the effects of ketanserin. Hypertension 1988;11:111-133.
56. Garg VC, Hassid A: Nitric-oxide generating vasodilators and cyclic guanosin monophosphate inhibit mitogenesis of rat vascular smooth muscle cells. J Clin Invest 1989; 83:1774-1777.
57. Cleophas TJM, Niemeyer MG: No-donors and angina pectoris: more than just symptomatic treatment? Neth J Med 1998;52:82-89.
58. Cleophas TJM, Niemeyer MG, van de Wall EE, et al: Nitrate induced headache in patients with stable angina pectoris: beneficial effect of starting on a low dosage. Angiology 1996;47:812-823.
59. Grimm RH, Flack JM, Grandits GA, et al: Long-term effects of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group. JAMA 1996;275:1549-1556.
60. Elliott WJ: ALLHAT: the largest and most important clinical trial in hypertension ever done in the USA. Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial. Am J Hypertens 1996;9:409-411.